Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171


Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib.

Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, Korn EL, Ma Y, Caldwell KL, Dong Z, Taylor PR, Dawsey SM.

Gastroenterology. 2005 Sep;129(3):863-73.


Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population.

Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR.

Cancer Res. 2006 Jul 1;66(13):6851-60.


Pilot randomized phase II study of celecoxib in oral premalignant lesions.

Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO.

Clin Cancer Res. 2008 Apr 1;14(7):2095-101. doi: 10.1158/1078-0432.CCR-07-4024.


Serum cytokine analysis in a positive chemoprevention trial: selenium, interleukin-2, and an association with squamous preneoplastic disease.

Roth MJ, Katki HA, Wei WQ, Qiao YL, Bagni R, Wang GQ, Whitby D, Dong ZW, Gail MH, Limburg PJ, Giffen CA, Taylor PR, Dawsey SM.

Cancer Prev Res (Phila). 2010 Jul;3(7):810-7. doi: 10.1158/1940-6207.CAPR-09-0269. Epub 2010 Jun 29.


Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China.

Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, Li JY, Blot WJ, Li B, Taylor PR.

Cancer. 1994 Sep 15;74(6):1686-92.


Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group.

Taylor PR, Li B, Dawsey SM, Li JY, Yang CS, Guo W, Blot WJ.

Cancer Res. 1994 Apr 1;54(7 Suppl):2029s-2031s.


Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.

Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA; Chemoprevention for Barrett's Esophagus Trial Research Group.

J Natl Cancer Inst. 2007 Apr 4;99(7):545-57.


Intervention and follow-up on human esophageal precancerous lesions in Henan, northern China, a high-incidence area for esophageal cancer.

Wang LD, Zhou Q, Feng CW, Liu B, Qi YJ, Zhang YR, Gao SS, Fan ZM, Zhou Y, Yang CS, Wei JP, Zheng S.

Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:159-72.


Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population.

Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1046-7.


Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.

Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC; Familial Adenomatous Polyposis Study Group.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7.


Endoscopic screening for esophageal squamous-cell carcinoma in high-risk patients: a prospective study conducted in 62 French endoscopy centers.

Dubuc J, Legoux J-, Winnock M, Seyrig J-, Barbier J-, Barrioz T, Laugier R, Boulay G, Grasset D, Sautereau D, Grigoresco D, Butel J, Scoazec J-, Ponchon T; Société Française d'Endoscopie Digestive.

Endoscopy. 2006 Jul;38(7):690-5.


Cytologic detection of esophageal squamous cell carcinoma and precursor lesions using balloon and sponge samplers in asymptomatic adults in Linxian, China.

Roth MJ, Liu SF, Dawsey SM, Zhou B, Copeland C, Wang GQ, Solomon D, Baker SG, Giffen CA, Taylor PR.

Cancer. 1997 Dec 1;80(11):2047-59.


[Preliminary report on the results of nutrition prevention trials of cancer and other common diseases among residents in Linxian, China].

Li JY, Li B, Blot WJ, Taylor PR.

Zhonghua Zhong Liu Za Zhi. 1993 May;15(3):165-81. Chinese.


Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.

Bardou M, Barkun AN, Ghosn J, Hudson M, Rahme E.

Clin Gastroenterol Hepatol. 2004 Oct;2(10):880-7.


Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.

Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators.

Circulation. 2006 Sep 5;114(10):1028-35.


A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia.

Farley JH, Truong V, Goo E, Uyehara C, Belnap C, Larsen WI.

Gynecol Oncol. 2006 Nov;103(2):425-30. Epub 2006 May 3.


Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the Dysplasia Trial in Linxian, China.

Dawsey SM, Wang GQ, Taylor PR, Li JY, Blot WJ, Li B, Lewin KJ, Liu FS, Weinstein WM, Wiggett S, et al.

Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):167-72.


Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.

Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ.

Clin Gastroenterol Hepatol. 2006 Feb;4(2):203-11.


p53 immunoexpression: an aid to conventional methods in the screening of precursor lesions of squamous esophageal cancer in patients at high-risk?

Fagundes RB, Melo CR, Pütten AC, Moreira LF, de Barros SG.

Cancer Detect Prev. 2005;29(3):227-32. Epub 2005 Apr 21.


Does daily alcohol and/or cigarette consumption cause low-grade dysplasia, a precursor of esophageal squamous cell carcinoma?

Kaneko K, Murakami Y, Katagiri A, Konishi K, Kubota Y, Muramoto T, Kushima M, Ohtsu A, Imawari M.

J Clin Gastroenterol. 2010 Mar;44(3):173-9. doi: 10.1097/MCG.0b013e3181bb837a.


Supplemental Content

Support Center